Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
Each line starts at 100 so growth is directly comparable
| Metric | RCAT | CDRE |
|---|---|---|
| Price | $6.15 | $24.97 |
| Change today | ▼ 3.00% | ▼ 2.08% |
| Market cap | $939.19M | $1.07B |
| Return, 3 months | -33.1% | -15.3% |
| Return, year to date | -22.4% | -38.3% |
| Return, 1 year | -57.1% | -34.5% |
| P/E (TTM) | -7.7 | 30.8 |
| P/B | 2.0 | 3.1 |
| P/E percentile vs own 5y | 48th | 19th |
| Dividend yield | – | 1.56% |
| Revenue growth (YoY, latest qtr) | +527.3% | +31.8% |
| Net profit growth (YoY) | -165.4% | -6.6% |
| Gross margin | 9.7% | 41.8% |
| Operating margin | -150.1% | 11.1% |
| Net margin | -136.3% | 5.3% |
| Return on equity | -34.4% | 10.6% |
| Analyst target vs. price | +169.4% | +77.5% |
| Analyst buy share | 86% | 83% |
| RSI (14) | 29 | 30 |
| 30-day volatility | 57.2% | 29.4% |
| Max drawdown, 1 year | -64.6% | -45.4% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
